Trevena (TRVN) Competitors $1.06 -0.03 (-2.84%) As of 05/22/2025 03:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock TRVN vs. SONN, LIXT, ADIL, CANF, OGEN, MBIO, SPRC, GLTO, SBFM, and IMCCShould you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Sonnet BioTherapeutics (SONN), Lixte Biotechnology (LIXT), Adial Pharmaceuticals (ADIL), Can-Fite BioPharma (CANF), Oragenics (OGEN), Mustang Bio (MBIO), SciSparc (SPRC), Galecto (GLTO), Sunshine Biopharma (SBFM), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Trevena vs. Sonnet BioTherapeutics Lixte Biotechnology Adial Pharmaceuticals Can-Fite BioPharma Oragenics Mustang Bio SciSparc Galecto Sunshine Biopharma IM Cannabis Sonnet BioTherapeutics (NASDAQ:SONN) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings. Is SONN or TRVN more profitable? Trevena's return on equity of 0.00% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonnet BioTherapeuticsN/A -408.93% -174.13% Trevena N/A N/A -119.55% Which has higher earnings and valuation, SONN or TRVN? Sonnet BioTherapeutics has higher revenue and earnings than Trevena. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonnet BioTherapeutics$1M3.55-$7.44MN/AN/ATrevena$443K2.29-$40.29M-$47.04-0.02 Do insiders and institutionals hold more shares of SONN or TRVN? 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, SONN or TRVN? Sonnet BioTherapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Trevena has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Do analysts rate SONN or TRVN? Sonnet BioTherapeutics presently has a consensus target price of $20.00, indicating a potential upside of 1,685.71%. Trevena has a consensus target price of $5.00, indicating a potential upside of 372.14%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Sonnet BioTherapeutics is more favorable than Trevena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Trevena 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to SONN or TRVN? In the previous week, Trevena had 1 more articles in the media than Sonnet BioTherapeutics. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Sonnet BioTherapeutics. Trevena's average media sentiment score of 0.87 beat Sonnet BioTherapeutics' score of 0.00 indicating that Trevena is being referred to more favorably in the news media. Company Overall Sentiment Sonnet BioTherapeutics Neutral Trevena Positive Does the MarketBeat Community favor SONN or TRVN? Trevena received 594 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 68.14% of users gave Trevena an outperform vote. CompanyUnderperformOutperformSonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38%TrevenaOutperform Votes61668.14% Underperform Votes28831.86% SummarySonnet BioTherapeutics beats Trevena on 8 of the 15 factors compared between the two stocks. Get Trevena News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVN vs. The Competition Export to ExcelMetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.02M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.029.0626.7119.71Price / Sales2.29251.51386.08120.53Price / CashN/A65.8538.2534.62Price / Book-0.106.456.774.50Net Income-$40.29M$143.98M$3.23B$248.22M7 Day Performance-15.28%0.38%0.48%-0.78%1 Month Performance-8.71%2.14%9.10%11.53%1 Year Performance-89.84%-0.33%18.56%8.99% Trevena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVNTrevena1.3198 of 5 stars$1.06-2.8%$5.00+372.1%-89.7%$1.02M$443,000.00-0.0240Analyst ForecastSONNSonnet BioTherapeutics2.0418 of 5 stars$1.33+3.9%$20.00+1,403.8%-35.6%$4.08M$1M0.0010LIXTLixte Biotechnology0.3311 of 5 stars$1.28+5.3%N/A-48.1%$4.03MN/A-0.744Positive NewsADILAdial Pharmaceuticals3.239 of 5 stars$0.61+1.6%$8.00+1,209.3%-49.4%$4.02MN/A-0.1820Analyst RevisionCANFCan-Fite BioPharmaN/A$1.10-0.9%$14.00+1,172.7%-56.3%$3.89M$674,000.00-0.618OGENOragenicsN/A$0.18+6.8%N/A-92.3%$3.87M$40,000.00-0.035MBIOMustang Bio0.0933 of 5 stars$1.13-3.0%$100.00+8,749.6%-89.3%$3.85MN/A-0.01100Positive NewsGap DownSPRCSciSparc0.6424 of 5 stars$0.35+2.3%N/A-73.5%$3.81M$1.31M0.004GLTOGalecto1.6497 of 5 stars$2.78+1.3%$10.00+260.4%-80.9%$3.67MN/A-0.1440Gap DownSBFMSunshine Biopharma1.8404 of 5 stars$1.35+8.0%$15.00+1,011.1%+74.5%$3.65M$34.87M-0.013Earnings ReportGap DownIMCCIM Cannabis0.5043 of 5 stars$1.61-2.4%N/A-52.6%$3.60M$54.03M-0.47340Positive NewsEarnings ReportGap Down Related Companies and Tools Related Companies SONN Alternatives LIXT Alternatives ADIL Alternatives CANF Alternatives OGEN Alternatives MBIO Alternatives SPRC Alternatives GLTO Alternatives SBFM Alternatives IMCC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVN) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVN Stock Free TRVN Stock Alerts